Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ABS-201 in Adult Participants With and Without Androgenetic Alopecia

NCT07317544 is registered in ClinicalTrials.gov with Absci Pty Ltd. as lead sponsor.

NCT NCT07317544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07317544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ABS-201 in Adult Participants With and Without Androgenetic Alopecia
Lead sponsor
Absci Pty Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 3, 2025
Completion date
July 31, 2028
Enrollment
227 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

androgenetic alopecia (aga), healthy volunteers - male and female